For research and educational purposes only. Not intended for human consumption.
VIP
Well Researched- •FDA Fast Track for COVID-19 ARDS (Aviptadil)
- •CIRS inflammatory marker correction
- •Neuroprotection mechanisms detailed
Vasoactive Intestinal Peptide | Immune Regulation & Neuroprotection
Overview
What is VIP?
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective properties. Acting through VPAC1 and VPAC2 receptors, VIP regulates immune function, vascular tone, circadian rhythms, and neurological health. The injectable form (Aviptadil) received FDA Fast Track designation for COVID-19 ARDS.
Key Benefits
Immune regulation and reduced inflammation, neuroprotection and circadian rhythm support, respiratory health improvement, direct CNS delivery bypassing BBB, correction of CIRS inflammatory markers.
Mechanism of Action
VIP binds to VPAC1 and VPAC2 receptors coupled to Gαs proteins, activating adenylate cyclase and increasing cAMP/PKA signaling. This leads to anti-inflammatory effects through inhibition of pro-inflammatory cytokines (IL-6, TNF-α) and modulation of immune responses.
Molecular Information
Pharmacokinetics
Research Indications
CIRS (Chronic Inflammatory Response Syndrome)
VIP nasal spray is the final step in the Shoemaker Protocol for CIRS from mold/biotoxin exposure. Corrects inflammatory markers refractory to other therapies.
Autoimmune Conditions
Research shows VIP downregulates inflammatory and autoimmune disease components.
Respiratory Inflammation
VIP has bronchodilatory and anti-inflammatory effects in airways.
Research Protocols
Disclaimer: VIP nasal spray is compounded off-label and not FDA-approved. For CIRS, complete Shoemaker Protocol steps 1-11 before starting VIP. Consult a specialist.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CIRS Protocol (Shoemaker) | 50mcg per spray, 4-8 sprays/day | 4x daily | Intranasal |
| General Immune Support | 50-100mcg | 2-4x daily | Intranasal |
| Starting/Sensitive Patients | 50mcg | 2x daily | Intranasal |
| Advanced/Maintenance | 100-200mcg | 2-4x daily | Intranasal |
Timing: Multiple daily doses maintain therapeutic levels due to short half-life. Morning dosing aligns with natural circadian VIP rhythms.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
VIP nasal spray is typically supplied pre-formulated by compounding pharmacies
Store in refrigerator at 2-8°C
Clear nasal passages before administration
Prime spray bottle before first use (2-3 pumps)
Insert nozzle into nostril, aim slightly outward
Spray while gently inhaling
Alternate nostrils between doses
Do not blow nose immediately after spraying
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Clear solution
Compounded VIP nasal spray should be clear and colorless.
Proper spray function
Should deliver consistent, fine mist.
Licensed compounding pharmacy
Source from accredited pharmacy with COA.
Temperature during shipping
VIP is temperature-sensitive. Ensure cold chain.
Cloudiness or particles
Indicates degradation - do not use.
What to Expect
- •Days 1-7: May experience mild nasal irritation initially
- •Week 1-2: Potential improvement in energy and sleep quality
- •Week 2-4: Reduction in inflammatory symptoms
- •Week 4-8: Progressive improvement in CIRS markers if applicable
- •Month 2+: Continued correction of inflammatory parameters
Side Effects & Safety
Side Effects
- •First dose should be administered under medical supervision with lab monitoring
- •Pre-VIP labs: TGF-β1, Lipase (baseline)
- •Stop immediately if abdominal pain develops or lipase elevates
- •Not FDA-approved as nasal spray - compounded off-label
- •Monitor blood pressure - VIP can cause vasodilation
- •Not recommended during pregnancy or breastfeeding
When to Stop
- •Abdominal pain
- •Elevated lipase
- •Significant blood pressure changes
- •Allergic reactions
- •As directed by specialist
References
3 StudiesIV Aviptadil in COVID-19 Respiratory Failure (2022)
Human | 196 patients | IV infusion | 60 days | 2-fold increased survival odds
Multicenter RCT showing Aviptadil increased 60-day survival odds 2-fold in critical COVID-19.
VIP Corrects CIRS (2013)
Human | CIRS patients | Nasal spray | Multiple months | Correction of inflammatory markers
VIP nasal spray corrects CIRS from water-damaged buildings, improving proteomics and transcriptomics.
IUPHAR VIP/PACAP Review (2012)
Review | VPAC1/VPAC2/PAC1 receptors | Comprehensive pharmacology
Definitive review of VIP receptor pharmacology and therapeutic potential.
Quick Start Guide
Research Disclaimer
VIP is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving VIP must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of VIP for any purpose. Consult qualified professionals for any research applications.